Celyad

Belgium
Mont-Saint-Guibert, Wallonia, Belgium, 1435

Company profile

Celyad company profile

Celyad is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Business identity

Contact email
[email protected]
Phone number
+32(0) 10 39 41 00
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2007-01-01, Year

Headquarters

Postal code
1435
Country code
BE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
10
Total equity funding
$148.5M
Last funding
Post IPO Equity / $1.2M / 2025-07-28
Last equity funding
Post IPO Equity / $1.2M
Investors
7
Lead investors
3
Founders
1
Articles
47
Exited on
2015-06-19

Founders and investors

Founders

Christian Homsy

Lead investors

CFIP CLYDFortress Investment GroupTolefi Group

Investors

Fortress Investment GroupGrifolsLife Sciences Research Partners V.Z.W.S.R.I.W.Tolefi Group